Association of Haemoglobin Level with Morbidity and Mortality of Patients with Locally Advanced Oesophageal Carcinoma Undergoing Radiotherapy — A Secondary Analysis of Three Consecutive Clinical Phase III Trials

Zhao, Kuaile; Liu, G.; Jia, Guanghong; Wang, Y.; Zhong, Lin; Yao, Weichao; Guo, Xiaomao; Wu, Gen-di; Zhu, Long-Xiang; Shi, Xiaoling

doi:10.1016/j.clon.2006.04.015

Cited by 19 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study on ESCC showed that the OS of patients with anemia was reduced [38]. Besides, the low Hb levels may have an impact on tolerance and recovery of chemoradiotherapy [39,40]. In a series of 123 ESCC patients with neoadjuvant chemoradiotherapy, the pathologic responses of tumors could be influenced by the Hb [39].…”

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

The aim of the present study was to investigate the survival and prognostic factors of patients who were with advanced esophageal squamous cell carcinoma (ESCC) and developed an esophageal fistula. The data from 221 patients with advanced ESCC developed esophageal fistula from January 2008 to December 2017 at the Harbin Medical University Cancer Hospital was retrospectively analyzed. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by the Cox proportional hazard models. The median survival time after a diagnosis of the esophageal fistula was calculated using the Kaplan–Meier method. We found that the pathogens infected by patients are common bacteria in nosocomial infection. Besides, the incidence rate of esophagomediastinal fistula was the highest (54.2%) in the lower third of the esophagus. Kaplan–Meier analysis revealed a median survival time of 11.00 months and a median post-fistula survival time of 3.63 months in patients who developed esophageal fistula in advanced esophageal cancer. In the univariate analysis, gender, therapies for ESCC before the development of fistula, type of esophageal fistula, treatment of esophageal fistula and hemoglobin (Hb) level were the factors with significant prognostic value. Gender, type of esophageal fistula and Hb level were identified as independent prognostic factors in further multivariate analysis. In summary, our study demonstrated that several factors are significantly related to patients with esophageal fistula and should be concerned about in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…local control rate for Tl tumors with an overall treatment time of 42-49 days was previously reported to be significantly higher compared with that of tumors with corresponding treatment times of >49 days (P<0.02) (11). In addition, previous studies have demonstrated an association between low hemoglobin levels and poor local control, i.e., pre-treatment anemia was an adverse factor for survival in patients with early-stage glottic carcinoma (16,17); this was not observed in the present study. There was a significant decrease in the 10-year overall survival rate in patients with pre-RT anemia compared with those without pre-RT anemia (52 vs. 68%, respectively) (18).…”

Section: Discussionmentioning

confidence: 91%

Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy

et al. 2020

View full text Add to dashboard Cite

The aim of the present study was to retrospectively investigate the risk factors of local failure for T1 glottic carcinoma irradiated with a prescription dose of 66 Gy. Between July 2006 and December 2017, 64 patients with T1 glottic squamous cell carcinoma treated with 66 Gy/33 fractions were analyzed for risk factors of local failure. The sex, age, performance status, T stage, overall treatment time, anterior commissure involvement, smoking status during/after treatment, histological tumor grade and pretreatment hemoglobin level were investigated. The maximum, mean and minimum doses, and the homogeneity index for the glottic larynx were calculated for dosimetric risk factors of local failure. The median follow-up duration was 51 months. Local failure was observed in 6 patients (9.5%). Among all risk factors, only the minimum dose to the glottic larynx was found to be significantly associated with local failure (P=0.025). The 5-year local control rates for a minimum dose to the glottic larynx of <65 and ≥65 Gy were 79 and 95%, respectively, with a statistically significant difference (P= 0.015). No patients exhibited grade ≥3 late adverse effects. The minimum dose to the glottic larynx was the only factor significantly associated with local failure. Thus, local control of T1 glottic carcinoma may improve with a minimum dose of ≥65 Gy to the glottic larynx. In conclusion, radiotherapy with a minimum prescription dose of ≥65 Gy to the glottic larynx appears to be safe and achieves a high local control rate for T1 glottic carcinoma.

show abstract

“…This drug has shown promise in a number of other cancers and may possess antineoplastic effects that are mediated through a number of pathways in addition to iron chelation alone. 18 …”

Section: Discussionmentioning

confidence: 99%

“…17 Previous studies in oesophageal cancer have estimated the incidence of anaemia on presentation to range from 20% to 45%. 18,19 Clearly, any benefit seen for patients treated with iron chelation therapy in terms of antineoplastic activity or chemosensitisation would be substantially negated by the development of iron deficiency and/or anaemia and its associated side effects.…”

mentioning

confidence: 99%

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy

Ford

Bedford²,

Pang

et al. 2014

annals

View full text Add to dashboard Cite

INTRODUCTIONThe incidence of oesophageal adenocarcinoma (OAC) is rising dramatically and overall survival remains extremely poor. Iron has been shown to potentiate tumourigenesis in OAC, and iron chelation therapy demonstrates promise in vivo as an adjunct to neoadjuvant and palliative chemotherapy. OAC, however, has traditionally been associated with iron deficiency anaemia. The aim of this study was therefore to formally quantify the iron status of OAC patients in order to guide the design of future clinical trials involving iron chelation therapy. METHODS Demographic and cancer specific data were collected prospectively from all patients presenting with OAC and gastric adenocarcinoma (GAC). Patients had haemoglobin, serum iron, serum ferritin and serum transferrin receptor (sTfR) levels measured to assess systemic iron status. In addition, the sTfR/log ferritin (sTfR-F) index was calculated. RESULTS Average haemoglobin, serum iron, serum ferritin, sTfR and sTfR-F index values for all patients presenting with OAC were within normal sex specific reference ranges. No statistical difference in iron status was observed between OAC patients presenting with resectable and advanced OAC. Patients with OAC are relatively iron replete compared with those presenting with GAC. Iron parameters were not significantly altered by standard neoadjuvant chemotherapy. CONCLUSIONS Patients presenting with resectable or advanced OAC could be considered as candidates for a clinical trial of iron chelation therapy as an addition to standard neoadjuvant or palliative treatments.

show abstract

Association of Haemoglobin Level with Morbidity and Mortality of Patients with Locally Advanced Oesophageal Carcinoma Undergoing Radiotherapy — A Secondary Analysis of Three Consecutive Clinical Phase III Trials

Cited by 19 publications

References 24 publications

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma

Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy

Contact Info

Product

Resources

About